Skip to main content
. 2024 Feb 5;2024(2):CD015219. doi: 10.1002/14651858.CD015219.pub2

McMahon 2022.

Study characteristics
Methods Randomized placebo‐controlled trial
Participants PCR‐confirmed COVID‐19
Interventions Favipiravir, placebo
Outcomes The primary endpoint was time to virological cure, defined as 2 successive swabs negative for SARS‐CoV‐2 by PCR. Secondary outcomes were progression of disease severity, symptom resolution, and safety.
Notes